Controls severe or incapacitating allergic conditions. ANDA 40572, held by Fresenius Kabi USA. Dexamethasone Sodium Phosphate.
As of Nov 21, 2026, ANDA 40572 (Dexamethasone Sodium Phosphate), held by Fresenius Kabi USA, was first approved by FDA on Apr 22, 2005, with 3 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 22, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexamethasone Sodium PhosphateEQ 10MG PHOSPHATE/ML · injectable;injection | Dexamethasone Sodium Phosphate | Rx |
| Jun 5, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 6, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 3, 2014 | Supplement 2Labeling · Standard review | Approved | |
| Apr 22, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters